Aileron Therapeutics Initiates Enrollment in Schedule Optimization Part of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent in Small Cell Lung Cancer (SCLC) Patients Being Treated with Topotecan

Aileron Therapeutics Announces Closing of Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares

Aileron Therapeutics Announces Pricing of Public Offering of Common Stock

Aileron Therapeutics Announces Proposed Public Offering of Common Stock

Aileron Therapeutics Announces Positive Interim Results from Phase 1b/2 Clinical Trial of ALRN-6924 for the Prevention of Topotecan-induced Toxicities During Treatment for Small Cell Lung Cancer

Aileron Therapeutics Announces Initiation of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent

Aileron Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Aileron Therapeutics Announces Plans to Release Interim Results from its Phase 1b/2 Myelopreservation Study in Mid-2020

Aileron Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer